[14] Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. 2010.
[15] Kahn JA, Rosenthal SL, Succop PA, Ho GYF, Burk RD. The interval between menarche and age of first sexual intercourse as a risk factor for subsequent HPV infection in adolescent and young adult women. J Pediatr. 2002;141:718–23.
[16]Burchell AN, Winer RL, de Sanjosé S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006;24 Suppl 3:S3/52–61.
[17]Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24 Suppl 1:S1–15.
[18] Abd EI All HS, Refaat A, Dandash K. Prevalence of cervical neoplastic lesions and human papilloma virus infection in Egypt: National cervical screening project. Infectious Agents and Cancer. 2007;2:12.
[19] Handbooks on the Cancer Prevention: Cervix Cancer Screening. Lyon, France: IARC Press; 2005.
[20] Monograph on the Evaluation of Carcinogenic Risks to Humans, Vol. 64: Human Papilloma
Viruses. Lyon, France: IARC; 1995.
[21] Moss SF, Blaser MJ. Mechanisms of disease: inflammation and the origin of cancer. Nat Clin Pract Oncol. 2005;2(2):90-97.
[22] Zur Hussain H. Intracellular surveillance of persisting viral infections. Human genital cancer results from deficient cellular control of papillomavirus gene expression. Lancet. 1986;2(8505):489-91.
[23] Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013;4:119–28.
[24] Rodriguez-Cedeira C, Sanchez-Blanco E, Alba A. Evaluation of association between vaginal infections and high risk human papillomavirus types in female sex workers in Spain. ISRN Obstet Gynecol. 2012;2012:240190.
[25] Koss LG, Wolinska WH. Trichomonas vaginalis cervicitis and its relationship to cervical cancer a cytohistogical study. Cancer. 1959;12:1171-93.
[26] Koskela P, Anttila T, Bjørge T, Brunsvig A, Dillner J, Hakama M, et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer. 2000;85:35–39.
[27] Tamim H, Finan RR, Sharida HE, Rashid M, Almani WY. Cervicovaginal co-infections with human papillomavirus and Chlamydia trachomatis. Diagn Microbiol Infect Dis. 2002;43(4):277-81.
[28] Chumduri C, Gurumurthy RK, Zadora PK, Mi Y, Meyer TF. Chlamydia infection promotes host DNA damage and proliferation but impairs the DNA damage response. Cell host and microbe. 2013;13(6):746-58.
[29] Adams AK, Wise-Draper TM, Wells SI. Human papillomavirus induced transformation in cervical and head and neck cancers. Cancers 2014;6:1793-820.
[30] Siddiqui MA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs 2006;66:1263-71.
[31] Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Drugs 2008;68:359-72.
[32]Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009;27:581-7.
[33] Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013;309:1793-802.
[34] Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011;7:1374-86.
[35] Romanowski B, Schwarz TF, Ferguson LM, Ferguson M, Peters K, Dionne M, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccin Immunother 2014;10:1155-65.
[36] Puig-Tintore LM, Cortes J, Castellsague X, Torne A, Ordi J, de San Jose S, et al.
Prevencion del cancer de cuello uterino ante la vacunacion frente al virus del papiloma humano. Prog Obstet Ginecol. 2006;46:5-62.
[37] Torne Bladea A, del Pino Saladriguesb M, Cusido Gimferrerc M, Alameda Quitlletd F,
Andia Ortize D. Guia de cribado del cancer de cuello de utero en Espana. Rev Esp Patol. 2014;47(Supl 1):1-43
[38] Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med 2012 Oct;136(10):1266-97.
[39] Stoler M, Bergeron C, Colgan TJ, Ferenczy A, Herrington S, Kim KR, et al. Tumours of the uterine cervix. Squamous cell tumours and precursos. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH, eds. WHO Classification of Tumours of Female Reproductive Organs. 4th ed. Lyon: International Agency of Research on Cancer (IARC); 2014. p. 169- 206.
[40] Oncoguía SEGO: Prevención del cáncer de cuello de útero. Guías de práctica clínica en cáncer ginecológico y mamario. Publicaciones SEGO. 2014 Oct.
[41] McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia: a retrospective cohort study. Lancet Oncol 2008 May;9(5):425-34.